ADCT ADC THERAPEUTICS SA revenue, earnings and financials
For the quarter ended June 30, 2026, ADC THERAPEUTICS SA reported revenue of $19.2M (up 2.2% from a year earlier), net income of −$16.6M and diluted EPS of −$0.11; over the last four quarters revenue was $79.6M and net income −$96.9M; for the fiscal year ended December 2025 revenue was $81.4M, up 14.9% on the year before.
ADCT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $81.4M, gross profit n/a, operating income −$121M, net income −$143M (margin -175.3%), EPS −$1.12
- Fiscal year ended Dec 2024: revenue $70.8M, gross profit n/a, operating income −$131M, net income −$158M (margin -222.8%), EPS −$1.62
- Fiscal year ended Dec 2023: revenue $69.6M, gross profit n/a, operating income −$166M, net income −$240M (margin -345.2%), EPS −$2.94
- Fiscal year ended Dec 2022: revenue $210M, gross profit n/a, operating income −$123M, net income −$157M (margin -74.9%), EPS −$2.01
ADCT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $19.2M (up 2.2% year over year), net income −$16.6M, EPS −$0.11
- Quarter ended Mar 31, 2026: revenue $20.9M (down 9.5% year over year), net income −$33.0M, EPS −$0.21
- Quarter ended Dec 31, 2025 (from the annual report): revenue $23.1M (up 36.4% year over year), net income −$6.39M, EPS $0.04
- Quarter ended Sep 30, 2025: revenue $16.4M (down 11.0% year over year), net income −$41.0M, EPS −$0.30
- Quarter ended Jun 30, 2025: revenue $18.8M (up 8.2% year over year), net income −$56.6M, EPS −$0.50
- Quarter ended Mar 31, 2025: revenue $23.0M (up 27.6% year over year), net income −$38.6M, EPS −$0.36
- Quarter ended Dec 31, 2024 (from the annual report): revenue $16.9M (up 0.7% year over year), net income −$30.7M, EPS −$0.26
- Quarter ended Sep 30, 2024: revenue $18.5M (up 27.4% year over year), net income −$44.0M, EPS −$0.42
- Quarter ended Jun 30, 2024: revenue $17.4M (down 9.7% year over year), net income −$36.5M, EPS −$0.38
- Quarter ended Mar 31, 2024: revenue $18.1M (down 4.9% year over year), net income −$46.6M, EPS −$0.56
- Quarter ended Dec 31, 2023 (from the annual report): revenue $16.8M, net income −$85.1M, EPS −$1.04
- Quarter ended Sep 30, 2023: revenue $14.5M, net income −$46.7M, EPS −$0.57
- Quarter ended Jun 30, 2023: revenue $19.3M, net income −$48.9M, EPS −$0.60
- Quarter ended Mar 31, 2023: revenue $19.0M, net income −$59.4M, EPS −$0.73
ADCT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$141M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$124M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$119M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$138M, share buybacks n/a
ADCT balance sheet
- Jun 30, 2026: cash $219M, total assets $279M, total liabilities $508M, shareholders' equity −$228M
- Mar 31, 2026: cash $231M, total assets $291M, total liabilities $508M, shareholders' equity −$216M
- Dec 31, 2025: cash $261M, total assets $323M, total liabilities $509M, shareholders' equity −$186M
- Sep 30, 2025: cash $235M, total assets $290M, total liabilities $528M, shareholders' equity −$238M
- Jun 30, 2025: cash $265M, total assets $322M, total liabilities $521M, shareholders' equity −$199M
- Mar 31, 2025: cash $195M, total assets $273M, total liabilities $511M, shareholders' equity −$238M
- Dec 31, 2024: cash $251M, total assets $322M, total liabilities $525M, shareholders' equity −$203M
- Sep 30, 2024: cash $274M, total assets $349M, total liabilities $521M, shareholders' equity −$172M
What is ADCT's revenue?
ADC THERAPEUTICS SA reported $79.6M of revenue over its last four quarters, through June 30, 2026.
Is ADCT profitable?
No. ADC THERAPEUTICS SA lost $96.9M over the last four quarters.
What is ADCT's EPS?
Diluted earnings per share over the last four quarters were −$0.58; −$0.11 in the latest quarter.